Life threatening angioedema in a patient on ACE inhibitor (ACEI) confined to the upper airway.
BACKGROUND
ACE inhibitors accounts for 8% of all cases of angioneurotic edema and the overall incidence is 0.1 to 0.7% of patients on ACE inhibitors. It is a leading cause (20-40%) of emergency room visits in the US with angioedema. We report a case of angioedema caused by ACE inhibitors confined to the upper airway after four years on treatment with Lisinopril which persisted for three weeks and required endotracheal intubation and subsequent tracheostomy due to delayed resolution. This case is one of the rare cases presented as upper airway edema which persisted for a long time.


METHODS
A 60-year-old Sudanese male patient with osteoarthritis in both knees underwent bilateral total knee replacement under single-shot epidural anesthesia. He had significant past medical history of type II diabetes, bipolar affective disorder and hypertension managed with Lisinopril for the past four years. Postoperatively after 10 hours the patient desaturated and developed airway obstruction requiring intubation. Laryngoscopy revealed an edematous tongue and upper airway and vocal cords were not visualized. In view of this clinical picture a provisional diagnosis of angioedema secondary to Lisinopril was made and it was discontinued. CT scan of the neck and soft tissues revealed severe airway edema with snugly fitting endotracheal tube with no peritubal air. A repeat CT neck on the tenth postoperative day showed no signs of resolution and an elective tracheostomy was performed on the eleventh postoperative day. C1 inhibitor protein and C4 levels were assayed to exclude hereditary angioedema and were found to be within normal range. Decannulation of tracheostomy was done after airway edema resolved on the twenty-fourth postoperative day as confirmed by CT scan. Subsequently he was transferred to the ward and discharged home.


CONCLUSIONS
ACEI induced angioedema is a well-recognized condition. Early diagnosis based on a high index of suspicion, immediate withdrawal of the offending drug followed by supportive therapy is the cornerstone of management.
Department of Anesthesia, ICU, Pain & Palliative Care, Al-Khor Hospital, Hamad Medical Corporation, Al-Khor, Qatar.
Abdulgafoor Muslim
AM
Tharayil
Department of Anesthesia, ICU, Pain & Palliative Care, Al-Khor Hospital, Hamad Medical Corporation, Al-Khor, Qatar.
Arshad Hussain
AH
Chanda
Department of Anesthesia, ICU, Pain & Palliative Care, Al-Khor Hospital, Hamad Medical Corporation, Al-Khor, Qatar.
Hakim Ahmad
HA
Shiekh
Department of Anesthesia, ICU, Pain & Palliative Care, Al-Khor Hospital, Hamad Medical Corporation, Al-Khor, Qatar.
Mohamed Saad
MS
Elkhatib
Department of Anesthesia, ICU, Pain & Palliative Care, Al-Khor Hospital, Hamad Medical Corporation, Al-Khor, Qatar.
Mohammed
M
Nayeemuddin
Department of Anesthesia, ICU, Pain & Palliative Care, Al-Khor Hospital, Hamad Medical Corporation, Al-Khor, Qatar.
Abdelhafiz Ali Ahmed
AA
Alshamandy
ACE inhibitor; angioedema; life threatening.